Cognition 2025

Acute effects of Hericium erinaceus extract on cognition and mood in healthy young adults: a double-blind crossover trial

A crossover RCT in 18 healthy 18–35-year-olds: a single 3 g dose of H. erinaceus fruiting body extract (10:1) did **not** improve composite cognition or mood versus placebo at 90 minutes; the only signal was better pegboard test performance. An important null finding: acute lion's mane effects in humans are unconfirmed.

Front Nutr 2025. Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults (PMID 40276537).

Rationale

Lion's mane is heavily promoted as a "neuroprotective nootropic" on the back of mouse data and small pilots. The authors tested the acute effect: does a single dose of fruiting-body extract change cognitive performance or mood in healthy young people — what consumers expect from a "capsule before work".

Methods

A double-blind randomized placebo-controlled crossover study: 18 healthy participants aged 18–35 received 3 g of 10:1 fruiting body extract or placebo in separate sessions. A test battery (executive function, working memory, psychomotor skill, attention, processing speed) and mood questionnaires were administered at baseline and 90 minutes after intake.

Results

  • Composite measures of global cognitive function and mood: NO significant effect — the extract did not differ from placebo.
  • Among individual tests, the only signal was improved pegboard test performance (psychomotor skill) at 90 minutes.
  • The authors interpret cautiously: any benefits may be task- or domain-specific rather than global.

Conclusions

A single dose of lion's mane fruiting body extract did not improve overall cognition or mood compared with placebo — an important negative result that contrasts with the mouse literature and supplement marketing.

Caveats

  • The card is valuable precisely for its null result: it balances the optimistic lion's mane cards and shows that an "instant nootropic effect" has not been demonstrated in people.
  • n=18 and a single dose — low power for weak effects; chronic use (4+ weeks) may differ — see the same team's chronic work in our card ezhovik-acute-stress-2023 (PMID 38004235).
  • Fruiting body extract was tested, not erinacine-containing mycelium — different chemical profiles, limited transfer.
  • This card replaces an unverifiable citation about a "crossover RCT, n=54, Frontiers in Pharmacology 2022, DOI 10.3389/fphar.2022.826741" — that DOI does not exist; the current source was verified directly.